HRP20220105T1 - Formulacija metotreksata - Google Patents
Formulacija metotreksata Download PDFInfo
- Publication number
- HRP20220105T1 HRP20220105T1 HRP20220105TT HRP20220105T HRP20220105T1 HR P20220105 T1 HRP20220105 T1 HR P20220105T1 HR P20220105T T HRP20220105T T HR P20220105TT HR P20220105 T HRP20220105 T HR P20220105T HR P20220105 T1 HRP20220105 T1 HR P20220105T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- buffer
- methotrexate
- flavor
- liquid pharmaceutical
- Prior art date
Links
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims 5
- 229960000485 methotrexate Drugs 0.000 title claims 5
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000019634 flavors Nutrition 0.000 claims 3
- 235000003599 food sweetener Nutrition 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 239000003765 sweetening agent Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 208000006045 Spondylarthropathies Diseases 0.000 claims 2
- 239000004376 Sucralose Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- 239000007968 orange flavor Substances 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 2
- 235000019408 sucralose Nutrition 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 239000004097 EU approved flavor enhancer Substances 0.000 claims 1
- 235000016623 Fragaria vesca Nutrition 0.000 claims 1
- 240000009088 Fragaria x ananassa Species 0.000 claims 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims 1
- 208000035561 Leukaemic infiltration brain Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010062164 Seronegative arthritis Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000019264 food flavour enhancer Nutrition 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- -1 methyl parahydroxybenzoate sodium salt Chemical class 0.000 claims 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Postupak za pripravu tekućeg farmaceutskog pripravka, naznačen time, da obuhvaća dodavanje pufera u slobodnu kiselinu metotreksatata za uspostavljanje pH vrijednosti na 6,6 do 7 i dodavanje jednog ili više konzervansa, spojeva za pojačavanje okusa, sredstava za zaslađivanje i/ili ko-otapala, pri čemu se puferska snaga pripravka nalazi u rasponu od 0,05 M do 0,1 M.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da se pH vrijednost pripravka postavlja na 6,6; 6,7; 6,8; 6,9 ili 7.
3. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da puferska snaga pripravka iznosi 0,05 M.
4. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pufera jest natrijev citratni pufer ili fosfatni pufer.
5. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da tekući pripravak jest otopina ili suspenzija.
6. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pripravak nadalje sadrži jedan ili više konzervansa, pri čemu jedan ili više konzervansa sadrže etil parahidroksibenzoat i/ili metil parahidroksibenzoat.
7. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pripravak nadalje sadrži jedan ili više spojeva za pojačavanje okusa i/ili sredstava za zaslađivanje, pri čemu jedan ili više spojeva za pojačavanje okusa i/ili sredstava za zaslađivanje sadrže okus naranče ili okus jagode i/ili sukralozu.
8. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da pripravak nadalje sadrži glicerol i/ili polietilen glikol.
9. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se dodaje natrijev citratni pufer ili fosfatni pufer u 0,4 do 20 mg/ml slobodne kiseline metotreksata, pri čemu pripravak sadrži:
PEG 400;
etil parahidroksibenzoat;
metil parahidroksibenzoat natrijevu sol;
glicerol;
okus naranče; i
sukralozu.
10. Tekući farmaceutski pripravak, naznačen time, da se može pripraviti postupkom prema bilo kojem od prethodnih patentnih zahtjeva.
11. Tekući farmaceutski pripravak prema patentnom zahtjevu 10, naznačen time, da je za oralnu primjenu.
12. Pripravak prema patentnom zahtjevu 10 ili 11, naznačen time, da je za uporabu u liječenju, gdje se primjena vrši oralnim putem.
13. Pripravak prema patentnom zahtjevu 10 ili 11, naznačen time, da je za uporabu u postupku primjene metotreksata kod pacijenta kojemu je potrebno liječenje, dok obuhvaća oralnu primjenu za pacijenta terapijski učinkovite količine tekućeg farmaceutskog pripravka prema bilo kojem od patentnih zahtjeva 10 ili 11.
14. Pripravak za uporabu prema patentnom zahtjevu 12 ili 13, naznačen time, da je liječenje za psorijazu, psorijatički artritis, sustavni dermatomiozitis, seronegativni artritis, reumatoidni artritis odraslih, otporan juvenilni reumatoidni artritis, poliartritičke oblike aktivnog juvenilnog idiopatskog artritisa (JIA), bolest usadak protiv domaćina, mikozne fungoide, spondiloartropatiju, spondiloartropatije, ankilozni spondilitis, neoplazme, akutnu limfoblastnu leukemiju, profilaksu meningealne leukemije, rak dojke, rak mokraćnog mjehura, rak glave, rak vrata, ne-Hodgkinov limfom, osteogenski sarkom, sarkom mekog tkiva kod odraslih, horiokarcinom ili rak pluća, hemoblastoze, ili bilo koje maligne tumore ili stanja za koja je propisan metotreksat.
15. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 12 do 14, naznačen time, da pacijent je dijete.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419261.1A GB201419261D0 (en) | 2014-10-29 | 2014-10-29 | Formulations |
| PCT/GB2015/053231 WO2016067024A1 (en) | 2014-10-29 | 2015-10-28 | Methotrexate formulation |
| EP15790211.5A EP3212237B1 (en) | 2014-10-29 | 2015-10-28 | Methotrexate formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220105T1 true HRP20220105T1 (hr) | 2022-04-15 |
Family
ID=52103589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220105TT HRP20220105T1 (hr) | 2014-10-29 | 2015-10-28 | Formulacija metotreksata |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11129833B2 (hr) |
| EP (1) | EP3212237B1 (hr) |
| JP (3) | JP2017533274A (hr) |
| CN (2) | CN107106485A (hr) |
| AU (1) | AU2015340373A1 (hr) |
| CA (1) | CA3002493C (hr) |
| CY (1) | CY1125033T1 (hr) |
| DK (1) | DK3212237T3 (hr) |
| ES (1) | ES2908447T3 (hr) |
| GB (2) | GB201419261D0 (hr) |
| HK (1) | HK1243638A1 (hr) |
| HR (1) | HRP20220105T1 (hr) |
| HU (1) | HUE057717T2 (hr) |
| IL (1) | IL251859A0 (hr) |
| LT (1) | LT3212237T (hr) |
| PL (1) | PL3212237T3 (hr) |
| PT (1) | PT3212237T (hr) |
| RS (1) | RS62971B1 (hr) |
| SI (1) | SI3212237T1 (hr) |
| WO (1) | WO2016067024A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201419261D0 (en) | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| CN107714653B (zh) * | 2017-11-27 | 2022-01-28 | 济南新科医药科技有限公司 | 一种稳定的可溶性甲氨蝶呤颗粒剂 |
| WO2019162756A2 (en) * | 2018-02-20 | 2019-08-29 | Ftf Pharma Private Limited | Liquid pharmaceutical compositions of anticancer drugs |
| WO2020044114A2 (en) | 2018-08-29 | 2020-03-05 | Ftf Pharma Private Limited | Methotrexate pharmaceutical composition |
| CN110269939A (zh) * | 2019-03-12 | 2019-09-24 | 武汉愔紫生物科技有限公司 | 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法 |
| KR20240042485A (ko) * | 2021-07-30 | 2024-04-02 | 에피제닉스 테라퓨틱스, 인크. | 클레미졸 제제 |
| CN115778897A (zh) * | 2022-12-15 | 2023-03-14 | 深圳市贝美药业有限公司 | 一种稳定的甲氨蝶呤药物制剂及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US101605A (en) * | 1870-04-05 | Gael fogelberg | ||
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| GB9402029D0 (en) * | 1994-02-03 | 1994-03-30 | Smithkline Beecham Plc | Novel formulation |
| US5925669A (en) | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
| US5593671A (en) * | 1994-07-01 | 1997-01-14 | American Cyanamid Company | Method of attenuating lung capillary leak in a mammal |
| US5770585A (en) | 1995-05-08 | 1998-06-23 | Kaufman; Robert J. | Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal |
| US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| WO2003007961A1 (en) | 2001-07-20 | 2003-01-30 | Iomed, Inc. | Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments |
| US20050101605A1 (en) * | 2003-11-07 | 2005-05-12 | Ahmed Salah U. | Oral liquid formulations of methotrexate |
| GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
| JPWO2010070705A1 (ja) * | 2008-12-17 | 2012-05-24 | 株式会社 メドレックス | アムロジピンの安定な含水経口製剤 |
| JP5722879B2 (ja) * | 2009-04-24 | 2015-05-27 | ハー・ルンドベック・アクチエゼルスカベット | １−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジンの塩の液体製剤 |
| GB201200192D0 (en) * | 2012-01-06 | 2012-02-22 | Rosemont Pharmaceuticals Ltd | Methotrexate composition |
| WO2015147018A1 (ja) * | 2014-03-28 | 2015-10-01 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
-
2014
- 2014-10-29 GB GBGB1419261.1A patent/GB201419261D0/en not_active Ceased
-
2015
- 2015-10-28 DK DK15790211.5T patent/DK3212237T3/da active
- 2015-10-28 EP EP15790211.5A patent/EP3212237B1/en active Active
- 2015-10-28 HR HRP20220105TT patent/HRP20220105T1/hr unknown
- 2015-10-28 JP JP2017542356A patent/JP2017533274A/ja active Pending
- 2015-10-28 WO PCT/GB2015/053231 patent/WO2016067024A1/en active Application Filing
- 2015-10-28 US US15/522,168 patent/US11129833B2/en active Active
- 2015-10-28 CN CN201580059139.6A patent/CN107106485A/zh active Pending
- 2015-10-28 PL PL15790211T patent/PL3212237T3/pl unknown
- 2015-10-28 RS RS20220132A patent/RS62971B1/sr unknown
- 2015-10-28 CN CN202310697145.0A patent/CN116747190A/zh active Pending
- 2015-10-28 GB GB1519049.9A patent/GB2531940B/en active Active
- 2015-10-28 AU AU2015340373A patent/AU2015340373A1/en not_active Abandoned
- 2015-10-28 LT LTEPPCT/GB2015/053231T patent/LT3212237T/lt unknown
- 2015-10-28 SI SI201531802T patent/SI3212237T1/sl unknown
- 2015-10-28 ES ES15790211T patent/ES2908447T3/es active Active
- 2015-10-28 PT PT157902115T patent/PT3212237T/pt unknown
- 2015-10-28 CA CA3002493A patent/CA3002493C/en active Active
- 2015-10-28 HU HUE15790211A patent/HUE057717T2/hu unknown
-
2017
- 2017-04-23 IL IL251859A patent/IL251859A0/en unknown
-
2018
- 2018-03-02 HK HK18103090.3A patent/HK1243638A1/zh unknown
-
2021
- 2021-06-09 JP JP2021096385A patent/JP2021138748A/ja active Pending
- 2021-08-26 US US17/458,006 patent/US11771701B2/en active Active
-
2022
- 2022-03-01 CY CY20221100172T patent/CY1125033T1/el unknown
-
2023
- 2023-05-17 JP JP2023081484A patent/JP2023103402A/ja active Pending
- 2023-09-28 US US18/374,215 patent/US20240024327A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2531940B (en) | 2017-04-26 |
| AU2015340373A1 (en) | 2017-05-18 |
| IL251859A0 (en) | 2017-06-29 |
| ES2908447T3 (es) | 2022-04-29 |
| CN116747190A (zh) | 2023-09-15 |
| CA3002493A1 (en) | 2016-05-06 |
| GB201519049D0 (en) | 2015-12-09 |
| EP3212237A1 (en) | 2017-09-06 |
| PL3212237T3 (pl) | 2022-04-19 |
| CY1125033T1 (el) | 2023-03-24 |
| US20210386746A1 (en) | 2021-12-16 |
| CA3002493C (en) | 2023-11-28 |
| US20240024327A1 (en) | 2024-01-25 |
| LT3212237T (lt) | 2022-02-25 |
| CN107106485A (zh) | 2017-08-29 |
| US11771701B2 (en) | 2023-10-03 |
| RS62971B1 (sr) | 2022-03-31 |
| HK1243638A1 (zh) | 2018-07-20 |
| DK3212237T3 (da) | 2022-03-07 |
| JP2021138748A (ja) | 2021-09-16 |
| GB201419261D0 (en) | 2014-12-10 |
| EP3212237B1 (en) | 2022-01-05 |
| WO2016067024A1 (en) | 2016-05-06 |
| GB2531940A (en) | 2016-05-04 |
| US11129833B2 (en) | 2021-09-28 |
| HUE057717T2 (hu) | 2022-06-28 |
| JP2023103402A (ja) | 2023-07-26 |
| SI3212237T1 (sl) | 2022-04-29 |
| US20170312281A1 (en) | 2017-11-02 |
| PT3212237T (pt) | 2022-04-14 |
| JP2017533274A (ja) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220105T1 (hr) | Formulacija metotreksata | |
| US11116724B2 (en) | Methotrexate composition | |
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| EA201490876A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| PH12021551077A1 (en) | A nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier | |
| BRPI0710483B1 (pt) | Dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e Kits úteis para o tratamento de doenças respiratórias | |
| JP2019504086A5 (hr) | ||
| KR20150011807A (ko) | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 | |
| JP2015527402A5 (hr) | ||
| HRP20220317T1 (hr) | Otkrivanje i liječenje nedostatka hormona rasta | |
| MXPA05003732A (es) | Metodos y composiciones para proporcionar glutamina. | |
| HRP20220691T1 (hr) | Poboljšanja u i u vezi s pripravcima | |
| HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| Wilson et al. | The influence of food on the absorption of acyclovir: a pharmacokinetic and scintigraphic assessment | |
| HRP20231448T1 (hr) | Primjena delgocitiniba za liječenje kroničnog ekcema ruku | |
| Nandi et al. | Albendazole-induced recurrent hepatitis | |
| RU2018125503A (ru) | Питательные композиции и детские смеси для стимуляции миелинизации в головном мозге | |
| EA201891860A1 (ru) | Фармацевтическая композиция пролонгированного высвобождения, содержащая цистеамин или его соли | |
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JOP20180124A1 (ar) | لقاح لفيروس الروتا ذو حجم جرعة منخفض مستقر حمضياً وخالى من المحلول المنظم | |
| Tab | t COLIC: INFANTILE | |
| GR1009069B (el) | Ποσιμα διαλυματα υψηλης συγκεντρωσης που περιεχουν υδροχλωρικη ρανιτιδινη | |
| EP2978403A1 (en) | Oral suspension for treating eosinophilic esophagitis | |
| TH14009A3 (th) | สูตรสารละลายในน้ำของริสเพอริโดน | |
| TH14009C3 (th) | สูตรสารละลายในน้ำของริสเพอริโดน |